Alithea Bio

Alithea Bio is a pioneering force in biotechnology research, dedicated to advancing precision medicine for immunotherapy. With a focus on the characterization of HLA-presented peptides and cutting-edge AI solutions, Alithea Bio is driving innovation in target validation and off-target toxicity assessment. The company operates out of its primary location in Freiburg im Breisgau, Baden Württemberg 79104, DE, and also has a presence at Robert-Rössle Straße, Berlin, BE 13125, DE.

Alithea Bio's AI-guided technology is geared towards delivering the most effective and safe drugs to each patient. By supporting biotech and pharmaceutical companies in their pursuit of superior TCR and TCRm immunotherapy, Alithea Bio is setting new standards in the industry. Their expertise in the absolute quantification of HLA peptides, combined with the world's largest HLA peptide database, positions them as leaders in off-target toxicity prediction, target discovery, and target validation.

Furthermore, Alithea Bio offers a highly sensitive neoantigen detection pipeline, NeoZoom, which is instrumental in optimizing cancer vaccine development. The HLA-Compass SaaS platform, a comprehensive quantitative database of HLA peptide presentation in healthy and tumor tissues, provides a suite of tools for off-target/safety evaluations. Alithea Bio is also at the forefront of understanding the potential immunogenicity risk of biotherapeutics through profiling HLA class II presented peptides. We invite the management team at Alithea Bio to create a customized and exclusive company showcase and product listing on our platform.